Brucella therapeutic preparations

Brucella can stimulate the body to produce a liquid immune response

Inactivated bovine Brucella

This product is a milky white uniform suspension and should not contain any lumps of bacteria or foreign matter that cannot be dispersed.

Used to treat subacute and chronic brucellosis.

1 Dilute the bacterial solution with physiological sodium chloride solution according to the indicated concentration as needed. 2 Use intravenous or intramuscular injection. (1) Intravenous injection: The injection site is the median vein of the elbow. Each injection is divided into two injections, with an interval of 1.5 to 2 hours. If the patient can tolerate it, the dose of the next injection can be increased as appropriate. For example: The dose of the first 1.2 injections is 3.0104, and the second 1.2 injections can be increased to 1.0105 and 1.5105 bacteria respectively. However, the maximum dose of the last 1.2 injections should not exceed 1.0106 and 1.5107 bacteria respectively. Each course of treatment may include several to more than ten injections, with an interval of 3 days, 5 days or 7 days between each injection. All doses and injection intervals should be determined based on the reaction and effect. (2) Intramuscular injection: The injection site is preferably the buttocks, and injections can be injected alternately into the muscles on both sides of the buttocks. Each course of treatment is about 6 to 10 times. The first injection can contain 1.0108 bacteria, and then gradually increase the volume, and finally use 1.0109 bacteria. The interval is 2 days, 3 days or 5 days.

1. After the vaccine is injected, the body temperature may rise, some as high as 40℃, and some people may have shock-like reactions. Pay close attention to such reactions and handle or treat them in time. 2. Abscesses may appear at the intramuscular injection site, and care should be taken to avoid muscle necrosis. Contraindications: This vaccine should not be used for treatment in the following conditions. 1. Severe heart disease, myocardial damage, significant cardiovascular sclerosis, endocarditis, acute parenchymal hepatitis and other diseases with liver damage, acute or chronic nephritis, active tuberculosis, and late pregnancy. 2. Extremely weak and severely anemic people, and people with low immune function. 3. People with repeated bleeding in the digestive tract and respiratory tract. 4. Patients with severe brucellosis. 5. People with bone damage, brucellotic spondylitis, osteomyelitis, hip arthritis, and pyorrhea. .

The following conditions should not be treated with this vaccine. 1 Severe heart disease, myocardial damage, significant cardiovascular sclerosis, endocarditis, acute parenchymal hepatitis and other diseases with liver damage, acute or chronic nephritis, active tuberculosis, late pregnancy. 2 Extremely weak and severe anemia, immunocompromised. 3 Recurrent bleeding in the digestive tract and respiratory tract. 4 Severe brucellosis. 5 Bone damage, brucellosis spondylitis, osteomyelitis, hip arthritis, pyorrhea.

Store at 2-8°C away from light.

1ml per vial

Lanzhou Institute of Biological Products Co., Ltd.

• Founded in:

  1983-04-04

• Address:

  No. 888, Yanchang Road, Chengguan District, Lanzhou City, Gansu Province

• Tax NO.:

  916200002243483486

• Registered Funds:

  1,816.94 million yuan

• Website:

  Log in to view

• Email:

  Log in to view